United States: Supreme Court Construes Key Provisions Of Biosimilar Statute

On June 12, 2017, the United States Supreme Court issued a unanimous opinion, written by Justice Thomas, in Sandoz, Inc. v. Amgen, Inc.,1 marking the High Court's first decision construing the Biologics Price Competition and Innovation Act of 2009 (the BPCIA). The BPCIA, codified under 42 U.S.C. § 262, governs the approval of a "biosimilar" version of a previously licensed biologic product (a reference product) of a manufacturer (a reference product sponsor). The BPCIA sets forth a complex scheme for the exchange of product and patent information between the biosimilar applicant and the reference product sponsor which is intended to provide a pathway to resolve patent disputes, including through patent litigation.

The Court addressed two key provisions under the BPCIA. The first provision, § 262 (l)(2)(A), provides that a biosimilar applicant "shall provide" to the reference product sponsor its biosimilar application and its manufacturing information within 20 days after the Food and Drug Administration (FDA) accepts the application. On this issue, the Supreme Court held that the provision is not enforceable by injunctive relief under federal law, but remanded for a determination as to whether injunctive relief is available under state law. The second provision, § 262 (l)(8)(A), provides that a biosimilar applicant "shall provide" to the reference product sponsor notice at least 180 days "before the date of the first commercial marketing of the biological product licensed under subsection (k) [the subsection directed to biosimilar applications]." On this issue, the Supreme Court held that a biosimilar applicant may provide notice of commercial marketing before FDA approval of the biosimilar application.

In the case, Sandoz had filed an application with the FDA for approval to market a biosimilar of Amgen's reference product, Neulasta® (filgrastim), under the brand name Zarxio®. Although Sandoz had notified Amgen of the filing of its biosimilar application, it declined to provide its application and manufacturing information under § 262 (l)(2)(A) and informed Amgen that it intended to market its biosimilar product immediately upon receiving FDA approval. Sandoz further informed Amgen that Amgen could sue for patent infringement immediately under § 262 (l)(9)(C), which provides that a reference product sponsor can bring a declaratory judgment action against a biosimilar applicant which "fails to provide the application and information required under paragraph (2)(A)."

Amgen sued Sandoz in the United States District Court for the Northern District of California for patent infringement and also asserted two claims under California state unfair competition law. Amgen alleged that Sandoz engaged in "unlawful" conduct when it failed to provide its biosimilar application and manufacturing information under § 262 (l)(2)(A), and also when it provided its notice of commercial marketing under § 262 (l)(8)(A) before, rather than after, its biosimilar application was approved by the FDA. Amgen sought injunctive relief to enforce both provisions of the BPCIA that it accused Sandoz of violating. Sandoz counterclaimed for declaratory judgment that the asserted patent was invalid and not infringed, and that it had not violated the BPCIA.

The District Court granted Sandoz partial summary judgment on the BPCIA claims and dismissed Amgen's state law unfair competition claims. Thereafter, a divided Court of Appeals for the Federal Circuit2 held that an injunction under federal law was not available to enforce § 262 (l)(2)(A) where the biosimilar applicant does not provide the reference product sponsor with its biosimilar application or manufacturing information, but that the 180-day notice of commercial marketing under § 262 (l)(8)(A) could not be provided until after the biosimilar application is approved and that the provision could be enforced by injunctive relief.

After the FDA licensed Sandoz's biosimilar application while the action was pending, Sandoz gave Amgen a second notice of commercial marketing. The Federal Circuit enjoined Sandoz from marketing its approved biosimilar product until 180 days after it provided its second notice of commercial marketing.

The Supreme Court granted certiorari, heard oral argument on April 26, 2017, and issued its unanimous opinion on June 12, 2017.

The Supreme Court affirmed the Federal Circuit's decision that § 262 (l)(2)(A)'s requirement that the biosimilar applicant provide its biosimilar application and manufacturing information was not enforceable under federal law by injunctive relief. In reaching this decision, the Supreme Court concluded that § 262 (l)(9)(C) authorizes the reference product sponsor to bring an immediate declaratory judgment action when the biosimilar applicant fails to provide the required information3 and that "[t]he remedy provided by § 262 (l)(9)(C) excludes all other federal remedies, including injunctive relief."4 However, the Supreme Court remanded the issue of whether injunctive relief was available under state law. The Supreme Court reasoned that whether the disclosure requirement of § 262 (l)(2)(A) is mandatory or conditional is an issue of state law, and if mandatory, a violation of the provision could be "unlawful" under state law. The Supreme Court further stated that if on remand the Federal Circuit determines that noncompliance with § 262 (l)(2)(A) is unlawful under California law, the Federal Circuit should proceed to determine whether the BPCIA preempts any additional remedy available under state law. The Supreme Court added that the Federal Circuit "is also of course free to address the pre-emption question first by assuming that a remedy under state law exists."5

In reversing the Federal Circuit's decision that § 262 (l)(8)(A)'s 180-day notice of commercial manufacturing could only be provided after the FDA approved the biosimilar application, the Supreme Court rejected the Federal Circuit's construction based on the use of the term "licensed" in the provision. Whereas the Federal Circuit had concluded that the term "licensed" meant that the FDA had to have licensed the biosimilar product before the 180-day notice under § 262 (l)(8)(A) could be given, the Supreme Court concluded that "[t]he statute's use of the word 'licensed' merely reflects the fact that, on the 'date of the first commercial marketing,' the product must be licensed."6 The Supreme Court therefore held that Sandoz had "fully complied with § 262 (l)(8)(A) when it first gave notice (before licensure)" and that "the Federal Circuit erred in issuing a federal injunction prohibiting Sandoz from marketing Zarxio until 180 days after licensure."7 Furthermore, because Amgen's state law claims were predicated on its argument that the BPCIA forbid prelicensure notice, the state law claims also failed.

Justice Breyer, in a concurring opinion, stated that "Congress implicitly delegated to the Food and Drug Administration authority to interpret [the] same terms" that the Supreme Court interpreted in its opinion, and set forth his understanding that the FDA "may well have the authority to depart from, or to modify, today's interpretation" of the BPCIA.8


1. 582 U.S. ___ (June 12, 2017), No. 15-1039.

2. Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015). The majority opinion of the Federal Circuit was written by Judge Lourie. Judges Newman and Chen concurred-in-part and dissented-in-part on different aspects of the majority opinion.

3. The Supreme Court disagreed with the Federal Circuit's alternative holding that 35 U.S.C. § 271(e)(2)(C)(ii) precluded enforcing § 262 (l)(2)(A) by federal injunction. The Supreme Court noted that § 271(e)(2)(C)(ii), which made the filing of a biosimilar application an act of patent infringement, did not also make an act of infringement, as the Federal Circuit had concluded, the failure to provide the biosimilar application and manufacturing information. Accordingly, the Supreme Court concluded that only § 262 (l)(9)(C), and not § 271(e)(2)(C)(ii), provided a remedy for a biosimilar applicant failing to provide its application and manufacturing information. Sandoz, slip op. at 11-12.

4. Id. at 12. In a footnote, the Supreme Court stated that "we express no view on whether a district court could take into account an applicant's violation of § 262 (l)(2)(A) (or any other BPCIA procedural requirement) in deciding whether to grant a preliminary injunction under 35 U.S.C. § 271 (e)(4)(B) or § 283 against marketing the biosimilar," citing case authority on a court's consideration of the "balance of equities" in deciding whether to grant a preliminary injunction. Id. at 13 n.2.

5. Id. at 15.

6. Id. at 16. The Supreme Court noted that § 262 (l)(8)(A) had only one timing requirement (that the biosimilar applicant had to provide notice at least 180 days prior to commercial marketing), whereas the Federal Circuit had interpreted the provision as having two timing requirements (the biosimilar applicant must provide notice after licensing and at least 180 days before commercial marketing). The Supreme Court pointed to another to another provision, § 262 (l)(8)(B), which did have two timing requirements as support for its interpretation that Congress only intended a single timing requirement for § 262 (l)(8)(A).

7. Id. at 16.

8. Id. at 1 (Breyer, J. concurring).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.